Achillion Disappoints Investors by Partnering HCV Assets with Janssen
By Heather Cartwright & Shruti Desai
Pharma Deals Review: Vol 2015 Issue 6 (Table of Contents)
Published: 29 Jun-2015
DOI: 10.3833/pdr.v2015.i6.2109 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
With the aim of developing an oral treatment regimen for chronic hepatitis C virus (HCV) infection that could work in as little as 6 weeks, Johnson & Johnson’s Janssen Pharmaceuticals has licensed worldwide development and commercialisation rights to Achillion Pharmaceuticals’lead HCV assets, including its Phase II second-generation NS5A inhibitor ACH-3102...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS